Santhera Pharmaceuticals is a listed, Swiss speciality pharmaceutical company focusing on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of severe neuromuscular diseases. The Company is currently investigating two compounds in four Phase II and III clinical programs in neuromuscular diseases and movement disorders.

Santhera’s skill-set includes:

• in vitro and in vivo biology (including animal facility)
• medicinal chemistry
• chemical analytics
• computational discovery
• pre-clinical development: safety pharmacology and toxicology
• technical development
• clinical development: clinical science and clinical operation
• regulatory affairs
• clinical pharmacology

Santhera also owns a large collection of standardized human muscle cells, particularly from DMD patients.

One of Santhera’s pre-clinical programs focuses on the development of small molecule calpain/proteasome inhibitors for the treatment of DMD.

Website

http://www.santhera.com/
 

Thomas Meier (PD, PhD): Track-record as senior-scientist in neuromuscular research. Awards include International Research Fellowship Award (NIH, USA) and a long-term fellowship by Human Frontier Science Program. 2000-2004: Founder and CEO of MyoContract Ltd and inventor of several patent applications.